SOMAÍ Pharmaceuticals has partnered with Georgelle Pharmaceutical Ltd. to bring an extensive range of cannabis-based medicines to Irish patients.

This marks SOMAÍ’s fifth international expansion, having already established operations in the UK, Australia, Germany, and Poland earlier this year.

Under a three-year agreement, SOMAÍ will supply Irish cannabis-prescribing clinics with a diverse cannabinoid-containing product line, including THC, CBD, and balanced oral solutions.

Read Also: Eli Lilly Pumps $800M Into Irish Operations To Meet Skyrocketing Demand For Mounjaro, Zepbound

The range will later expand to terpene-infused oral solutions and inhalation extracts, designed to address specific patient needs.

SOMAÍ’s founder and interim CEO, Michael Sassano, said, “Bringing Irish patients a full range of products and choices will further increase the range of demographics that need medicinal cannabis and have suffered with few options to treat themselves.”

The partnership aims to improve accessibility to cannabis-based medicines in Ireland, where patients have had limited options for treatment. Daniel O’Brien, CSO of Georgelle, expressed enthusiasm about the collaboration, saying,

“We admire [SOMAÍ’s] commitment to innovation and making a positive impact… to significantly improve the portfolio of available medicines for Irish patients.”

This move positions SOMAÍ as a leader in the Irish medical cannabis market, continuing its mission to offer patients enhanced treatment options tailored to their needs.

Get Benzinga’s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you’re serious about the business, you can’t afford to miss out.

Cover: AI generated image